Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
3 results loaded, newest first. End of these results.
The company said brelovitug met the Phase 3 primary endpoint at Week 24 in both dose arms. Mirum also reported 48-week Phase 2b data showing deeper viral suppression and no new safety signals.
The investor call will also include 48-week data from the study’s Phase 2b portion.
Mirum Pharmaceuticals will hold an investor call on Sept. 28, 2026 at 8:30 a.m. ET to share topline results from the Phase 3 AZURE-1 study of brelovitug in chronic hepatitis delta. The company also plans to provide 48-week data from the Phase 2b portion of the study.